
The real-world analysis examined outcomes in 146 mCRPC patients treated with LuPSMA. Of these, 30% received subsequent systemic therapy, mainly cabazitaxel-based chemotherapy. Post-LuPSMA PSA50 response was seen in 28% of evaluable patients, with a median survival of 7.6 months from further therapy initiation. Despite hematologic toxicities, treatments were largely tolerable, underscoring the need for continued innovation in post-LuPSMA mCRPC management.
Like
Save
Share